China, Gardasil and Merck

Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US pharmaceutical giant made the call earlier this week to halt shipments.
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country. | The recent decline of Merck & Co.
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
Merck stops Gardasil shipments to China, hitting 2025 outlook
Merck’s Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 billion in Gardasil sales by 2030 in light of the decision to stop shipments to China.
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling produ
Merck's 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange,
Merck Stock Loses 9% on Vaccine Shipment Halt to China
Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical
Merck Stock Tumbles on Weak Guidance, Bad News in China for Gardasil Sales
Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck’s Gardasil HPV vaccine in China, disclosed six months ago, has unsettled investors,
Dayton Daily News1d
Doctor encourages use of HPV vaccine as virus linked to multiple cancers increases among younger people
As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...
cidrap.umn1d
Meta-analysis finds high rates of non-vaccine, high-risk HPV cervical infections, even in vaccinated women
But rates of types 31/33/45, 47, and 45 were lower in vaccinated women, which the authors said suggests that the vaccines ...
The Pharma Letter1d
Merck & Co tanks as Gardasil woes hit guidance
US pharma giant Merck & Co opened Tuesday’s trading 10% lower after announcing its annual and fourth quarter financial ...
IFLScience7d
HPV Vaccines And Cervical Cancer Prevention: Where Are We Now?
HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...
Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.